Abrysvo (PF-06928316) / Pfizer - LARVOL DELTA

Cost-Effectiveness Analysis of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for the Prevention of RSV Illness Among Infants in Hong Kong. (PubMed, Int J Infect Dis) - "Year-round RSVpreF maternal vaccination would substantially reduce RSV's clinical and economic burden among infants in Hong Kong and would be a cost-effective program."

HEOR • Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2-<18 Year Olds. (PubMed, Vaccines (Basel)) - "RSV-A and RSV-B neutralizing titer geometric mean fold rises from before to 1 month after vaccination with RSVpreF 60 and 120 µg, which were 17.7-20.6 and 42.8-39.8, respectively, in 2-<5 year olds, and 19.0-23.5 and 20.3-20.3, respectively, in 5-<18 year olds. RSVpreF was safe, well tolerated, and elicited immune responses in RSV-seropositive 2-<18-year-old participants, supporting further clinical development in this pediatric population, including those with chronic conditions."

Journal • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland. (PubMed, Arch Dis Child) - "Uptake of the maternal vaccine was influenced by barriers to access, informational gaps and perceived safety concerns. Improved vaccine delivery, enhanced awareness and personalised antenatal counselling are essential to increase vaccine uptake. There is an urgent need to address structural inaccessibility and provide tailored antenatal education to address informational gaps. Ongoing qualitative research is crucial to guide targeted public health interventions ahead of future RSV seasons."

Journal • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Impact of nirsevimab and maternal Abrysvo immunisation on socio-economic disparities in RSV SARI incidence in Lyon, France, 20182025 (ESCMID Global 2026) - No abstract available

Examining Rates of and Disparities in Receipt of the ABRYSVO Vaccine for Respiratory Syncytial Virus among Pregnant Patients Greater than 32 Weeks of Gestation (PAS 2026) - No abstract available

Clinical • Respiratory Diseases • Respiratory Syncytial Virus Infections

Prevention of respiratory syncytial virus in children (PubMed, Ugeskr Laeger) - "Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

Real World Efficacy/Effectiveness and Immunogenicity of Maternal RSVpreF Vaccination: A Living Systematic Review and Meta-Analysis (RSVVW 2026) - "Included studies and meta-analyses are publicly released through the Safe in Pregnancy & Safe in Children hub as evidence accrues. This LSR-MA provides a comprehensive synthesis of the expanding evidence on maternal RSVpreF VE, supporting timely interpretation of emerging real-world data with robust methodological quality."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Review • Respiratory Diseases • Respiratory Syncytial Virus Infections

Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-Associated Cardiac Hospitalizations and Emergency Department Admissions without Acute Respiratory Infection (RSVVW 2026) - "Effectiveness against RSV-related non-ARI cardiac hospitalization/ED visits was 74% (29─91) across two seasons, and 79% (26–94) and 71% (-58─95) in the first and second seasons after vaccination, respectively (Table 2). These findings suggest that Abrysvo effectively reduced RSV-associated cardiac hospitalization/ED visits without an ARI diagnosis and may help mitigate cardiac morbidity in older adults beyond clinically apparent acute respiratory infection."

Clinical • Real-world • Real-world evidence • Heart Failure • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Effectiveness of Bivalent RSV Prefusion F Protein–based Vaccine for Preventing RSV and Cardiorespiratory Hospitalizations in Older Adults: The DAN-RSV Trial (RSVVW 2026) - "The incidence of serious adverse events was similar in the two groups. Among adults 60 years of age or older, the RSVpreF vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine."

Clinical • Cardiovascular • Geriatric Disorders • Respiratory Diseases • Respiratory Syncytial Virus Infections

Protocol for a multi-country networK evaluation of the effectiveness and impact of mAternal RSV vaccination on sHort and Long-term RSV Outcomes among infants and children: The KAHLO study (RSVVW 2026) - "The KAHLO study will quantify individual and population-level benefits of maternal RSVpreF on infant short- and long-term outcomes, including sequelae from wheeze and asthma. The platform has the potential for expansion to other settings."

Clinical • Asthma • Immunology • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Public Health and Economic Impact of Complementary Strategy (RSVpreF Vaccine/Nirsevimab) VS. Nirsevimab Alone in the Prevention of RSV Infections in the Italian Infant Population (RSVVW 2026) - "However, the complementary strategy would provide greater coverage, prevent more hospitalizations, and yield lower total costs than nirsevimab alone. Increased RSVpreF coverage would further enhance economic and public health benefits, resulting in fewer cases and lower economic impact."

Clinical • HEOR • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Advancing Infant Protection Against Respiratory Syncytial Virus: Clinical Impact of Passive Immunisation Strategies (RSVVW 2026) - "Pooled analyses confirm ~80% effectiveness of nirsevimab in preventing RSV-associated hospital or ICU admissions...Merck's clesrovimab (MK-1654) recently showed an ≈84% reduction in infant RSV hospitalizations through 5 months in a Phase 2/3 trial, with no new safety signals. With these new tools, routine monthly palivizumab (used for decades in high-risk infants) is being phased out in favor of once-per-season antibodies or maternal vaccines...Current evidence demonstrates high efficacy. Ongoing surveillance is needed to monitor rare outcomes, but these interventions represent powerful new tools for infant RSV prevention."

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Preliminary Evidence of Reduced RSV Infection in Maternal RSVpreF Recipients in the MATISSE Infant Efficacy Trial (RSVVW 2026) - P3 | "This preliminary evidence of infection reduction in maternal participants presents a possible future area for study of potential additional benefits of maternal vaccination. (NCT04424316)"

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) in Pregnant Individuals Living With HIV (RSVVW 2026) - P3 | "These results support maternal RSVpreF vaccination in individuals living with HIV for prevention of RSV-LRTI in HEU infants. (NCT06325657)."

Clinical • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Effectiveness of maternal RSVpreF vaccination against RSV in hospitalised infants ≤6 months: preliminary results from a multicentre test-negative design study in Australia, 2025 (STREETON Study) (RSVVW 2026) - "These real-world findings demonstrate high VE of RSVpreF vaccination in pregnancy against hospitalisation due to RSV-LRTD and RSV-ARI in infants ≤6 months in the first year following introduction. Future analyses with larger sample sizes will evaluate VE within key subgroups and stratifications important for informing vaccine policy and provide more granularity of VE by infant age."

Clinical • Respiratory Diseases • Respiratory Syncytial Virus Infections

Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Acute Respiratory Illness (ARI) Hospitalizations and Emergency Department Admissions over Two RSV Season (RSVVW 2026) - "Waning was pronounced among immunocompromised individuals. These results expand on prior data by evaluating endpoints through two seasons and by RSV subtype."

Clinical • Real-world • Real-world evidence • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Incremental Benefits of Maternal RSV Vaccination On Infant Outcomes Across Different Gestational Age Windows in Low- and Middle-Income Countries (RSVVW 2026) - "Policy scenarios comparing ≥24, ≥28, or ≥32 weeks' gestation maternal RSV vaccination windows found that wider intervals provided additional benefits for preventing neonatal RSV disease. The results are intended to inform policy decisions and optimise infant protection, particularly in low- and middle-income countries where ANC attendance by gestational age may limit current maternal vaccine delivery."

Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Bivalent RSVpreF reduces the risk of laboratory-confirmed RSV infection in nursing home residents across two seasons (RSVVW 2026) - "Among NH residents, a geriatric and frail population, bivalent RSVpreF vaccination was associated with a meaningful reduction in the risk of laboratory-confirmed RSV infection that persisted across two seasons. These findings support the use of RSV vaccination as an effective strategy to reduce the high RSV disease burden in long-term care settings."

Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory syncytial virus (RSV) neutralizing antibodies among individuals vaccinated with RSVpreF during pregnancy and their infants (RSVVW 2026) - "High CMRs were observed and, among vaccinated, increased as the interval between vaccination and delivery increased, indicating earlier vaccination within the recommended gestational age range results in higher antibody transfer to infants. Study enrollment, longitudinal specimen collection, and testing are ongoing."

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Qualification of multiplex immunoassays for the measurement of RSV antibodies in the mother-infant dyad. (RSVVW 2026) - "Three multiplex electrochemiluminescence immunoassays (ECLIAs) will be qualified for the quantification of respiratory syncytial virus (RSV)-specific antibodies in the mother–infant dyad in support of DMID clinical trial protocol 24-0003, a Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM), Infant Nirsevimab (BEYFORTUSTM) Immunization, or Both Products During the First Year of Life ("PROMISE")...The tools developed have translational value. The qualified methods will have broader applicability and can inform the design and bioanalytical characterization of other immunological assays to support clinical study endpoints."

Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Vaccination in pregnancy with RSVpreF elicits substantial and significant RSV-specific IgA, IgG and total secretory antibody titers in human milk, 11-31-fold higher compared to unvaccinated controls (RSVVW 2026) - "Enrollment and assessment of Ab longevity and functionality are ongoing. Post-licensure vaccine effectiveness studies will evaluate benefits conferred via milk-feeding."

Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Budget impact analysis of maternal vaccination with RSVpreF for Prevention of Respiratory Syncytial Virus among Infants from public healthcare perspectives in Egypt (RSVVW 2026) - "However, total vaccination costs of EGP 8,578.1 million ($179.3 million) resulted in a modest net budget increase, with a budget impact of EGP 15.92 ($0.3) PMPY. Use of RSVpreF vaccination among pregnant women could reduce RSV-LRTI clinical burden, with an acceptable budget increase per covered life in public scenario."

HEOR • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Advancing RSV vaccination strategies for older adults: insights of the Adult Immunization Board meeting (RSVVW 2026) - "Several adult vaccines—including the recently introduced RSV vaccines (Arexvy, Abrysvo, mRESVIA)—show strong efficacy or effectiveness, yet recommendations and funding remain uneven...Vaccination should be treated as an investment in healthy ageing, supporting functional ability and independence. With older adults now outnumbering young children globally, it is essential to ensure consistent, accessible protection across all recommended adult vaccines, including effective and appropriately funded RSV vaccination."

Clinical • Respiratory Syncytial Virus Infections

Cost-Effectiveness Analysis of Complementary Strategy to protect infants in Romania using Maternal Vaccination with Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine and Palivizumab (RSVVW 2026) - "From both societal and healthcare perspectives, RSVpreF in combination with palivizumab was dominant (i.e., cost saving) compared to palivizumab alone. A complementary prophylaxis of maternal RSVpreF vaccine and palivizumab would be a cost-saving strategy compared to palivizumab alone for preventing RSV-related disease in infants in Romania."

Cost effectiveness • HEOR • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Public Health and Economic Impact of Adult Vaccination with The Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Romania (RSVVW 2026) - "This would result in RSVpreF averting a total €66.2 million (M; €49.8M in medical care costs; €16.4M in indirect costs). Implementing a year-round RSVpreF vaccination program would substantially reduce the clinical and economic burden of RSV among adults at increased risk of severe RSV in Romania."

Clinical • HEOR • Infectious Disease • Influenza • Respiratory Diseases • Respiratory Syncytial Virus Infections